Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study

Abstract

Background:

Several new antithrombotic therapies have emerged for the treatment of acute coronary syndrome (ACS). We sought to assess contemporary patterns of antithrombotic therapies use in patients with ACS.

Methods and results:

EYESHOT (EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units) was a nationwide, prospective registry aimed to evaluate antithrombotic strategies employed in patients admitted to intensive cardiac care units (CCUs) for an ACS in Italy. Over a three-week period, 203 CCUs enrolled 2585 consecutive patients: 41.2% with ST-elevation myocardial infarction (STEMI) and 58.8% with non-ST elevation ACS (NSTE-ACS). During hospitalisation, low-molecular-weight heparins, aspirin, and clopidogrel were the most commonly used antithrombotic therapies. Among patients treated with percutaneous coronary intervention (PCI, n=1755), any crossover of heparin therapy occurred in 30.8% of cases, while switching from one P2Y₁₂ inhibitor to another occurred in 3.6% of cases in the CathLab and in 14.2% before discharge. Of the 790 patients who did not receive revascularisation, switching of a P2Y₁₂ inhibitor occurred in 5.7% of cases. At discharge, a new P2Y₁₂ inhibitor (ticagrelor or prasugrel) in association with aspirin was prescribed in 59.5% of STEMI and 33.9% of NSTE-ACS patients: the most powerful predictor for prescription was PCI (odds ratio (OR) 6.18; 95% confidence interval (CI) 4.76–8.01; p<0.0001), whereas age ≥75 years was strongly associated with clopidogrel use (OR 0.28; 95% CI 0.22–0.36; p<0.0001).

Conclusions:

The EYESHOT registry shows the current pattern of antithrombotic treatments for ACS patients admitted to Italian CCUs and provides insights which may help to improve the clinical care of such patients.

Keywords

Acute coronary syndrome antithrombotic therapy prasugrel ticagrelor heparins bivalirudin

Get full access to this article

View all access options for this article.

References

Wright

Anderson

Adams

.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57: e215–367.

Hamm

Bassand

Agewall

.; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.

Steg

James

Atar

Badano

.; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.

Subherwal

Peterson

Dai

. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention. A report from the National Cardiovascular Data CathPCI Registry. J Am Coll Cardiol 2012; 59: 1861–1869.

Eagle

Lim

Dabbous

., for the GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month post-discharge death in an international registry. JAMA 2004; 291: 2727–2733.

Subherwal

Bach

Chen

. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation 2009; 119: 1873–1882.

Rao

Pratt

Berke

. Thrombolysis In Myocardial Infarction (TIMI) Trial – Phase I: Haemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1–11.

Goodman

Huang

Yan

., Expanded Global Registry of Acute Coronary Events (GRACE2) Investigators. The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. Am Heart J 2009; 158: 193–201.

Abu-Assi

Gracía-Acuña

Ferreira-González

. Evaluating the Performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with non-ST-segment elevation acute myocardial infarction. Circulation 2010; 121: 2419–2426.

10.

Puymirat

Taldir

Aissaoui

. Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv 2012; 5: 893–902.

11.

Di Chiara

Chiarella

Savonitto

.; BLITZ Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network: The BLITZ study. Eur Heart J 2003; 24: 1616–1629.

12.

Alonso

Gore

Awad

.; GRACE Investigators. Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: Results from the GRACE registry. Eur Heart J: Acute Cardiovasc Care 2013; 2: 280–291.

13.

Mandelzweig

Battler

Boyko

.; Euro Heart Survey Investigators. The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006; 27: 2285–2293.

14.

Masoudi

Ponirakis

Yeh

. Cardiovascular care facts: A report from the national cardiovascular data registry: 2011. J Am Coll Cardiol 2013; 62: 1931–1947.

15.

Menees

Peterson

Wang

. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med 2013; 369: 901–909.

16.

Mahaffey

Pieper

Lokhnygina

.; SYNERGY Investigators. The impact of postrandomization crossover of therapy in acute coronary syndromes care. Circ Cardiovasc Qual Outcomes 2011; 4: 211–219.

17.

Gore

Spencer

Goldberg

.; GRACE Investigators. Use of heparins in Non-ST-elevation acute coronary syndromes. Am J Med 2007; 120: 63–71.

18.

Xanthopoulou

Deftereos

Sitafidis

. In-hospital bleeding events in acute coronary syndrome patients undergoing percutaneous coronary intervention in the era of novel P2Y12 inhibitors: Insights from the GReek AntiPlatelet rEgistry-GRAPE. Int J Cardiol 2014; 174: 160–162.

19.

Loh

Pendyala

Kitabata

. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2013; 111: 841–845.

20.

Husted

James

Becker

.; PLATO study group. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: A substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012; 5: 680–688.

21.

James

Roe

Cannon

.; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: Substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. Br Med J 2011; 342: d3527.

22.

Held

Asenblad

Bassand

. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011; 57: 672–684.